ACTUATE THERAPEUTICS, INC. (ACTU): Entry into a Material Definitive Agreement
ACTUATE THERAPEUTICS, INC. (ACTU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering CHICAGO, IL and FORT WORTH, TX, October 27, 2026 — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on devel
- Instrument
- common stock and warrants
- Gross proceeds
- approximately $11.0 million
- Shares
- 30,985,900 shares
- Price per share
- $0.71 per set of securities
- Use of proceeds
- working capital and general corporate purposes
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The $11 M capital raise provides working‑capital but introduces dilution, likely pressuring the share price in the near term.
Market read
Primary disclosure of a modest equity raise for a micro‑cap biotech, offering a short‑term trading opportunity.
What to watch
Warrant exercise price and optionality may provide additional upside if the stock rallies, partially offsetting dilution.
Background
Actuate Therapeutics is a clinical‑stage biopharma developing elraglusib for hard‑to‑treat cancers. The company filed an 8‑K to disclose a public offering.
Ticker impact
Actuate Therapeutics announced pricing of an $11.0 million underwritten public offering of 30.9 million shares and warrants.
likely pressure as the market prices in dilution from the $11 M raise
Primary 8‑K filing, first report of the offering, with clear terms and expected closing today.
Market effects
Adds modest capital to the clinical‑stage biotech sector, may prompt peers to consider similar financing.
Limited to US biotech investors; no broader regional effect.
Low global impact; primarily relevant to ACTU shareholders and biotech capital markets.
Counterpoint
The raise could fund critical R&D milestones, potentially supporting a longer‑term upside despite short‑term dilution.
Key entities
- companyActuate Therapeutics, Inc.
Clinical‑stage biopharma issuing new shares and warrants.
- underwriterNewbridge Securities Corporation
Sole book‑running manager for the offering.

